Hepatera and MYR plan hepatitis D-Day

Private Russian biotech company Hepatera and its German development partner MYR have early data suggesting that their entry inhibitor Myrcludex B may be an option for treating hepatitis delta, as well as the more well-known hepatitis B virus.